Similarly to HSPB1, CCND2 methylation displayed an HR of 0.86 [95% CI 0.75-0.98] (Table 3) indicating that higher levels of methylation were associated to lower risk of prostate cancer death, consistent with the role of activated CCND2 as an oncogene. This evidence concerns the gene HSPB1 and prostate cancer.